Ptc Therapeutics (PTCT) Net Cash Flow (2012 - 2026)

Ptc Therapeutics' Net Cash Flow history runs 15 years deep, the most recent figure standing at $218.4 million for Q2 2026.

• In Q2 2026, Net Cash Flow rose 145.85% year-over-year to $218.4 million; the TTM figure through Jun 2026 stood at $33.6 million (down 90.28% YoY), while the FY2025 annual figure was $180.3 million, down 6.27% from the prior year.
• Net Cash Flow for Q2 2026 stood at $218.4 million, up from -$146.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $695.2 million in Q1 2025, with the low at -$476.4 million in Q2 2025.
• The 5-year median for Net Cash Flow is -$30.1 million (2023), against an average of $47.6 million.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow jumped 4371.86% in 2022, then plunged 536.62% in 2025.
• Ptc Therapeutics' Net Cash Flow stood at $169.4 million in 2022, then surged by 151.35% to $425.8 million in 2023, then slumped by 37.95% to $264.2 million in 2024, then advanced by 14.41% to $302.2 million in 2025, then declined by 27.73% to $218.4 million in 2026.
• Business Quant data shows PTCT's Net Cash Flow at $218.4 million in Q2 2026, -$146.4 million in Q1 2026, and $302.2 million in Q4 2025.